Skip to main content
SpringerLink
Log in

Kommentar

ACE-Hemmer und das Lungenkrebsrisiko - was Ärzte bedenken sollten

ACE inhibitors and the risk of lung cancer. What doctors should consider

  • FB_Seminar
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Med. Klinik mit SP Nephrologie, Charité - Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany

    Markus van der Giet

Authors
  1. Markus van der Giet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus van der Giet.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Giet, M. ACE-Hemmer und das Lungenkrebsrisiko - was Ärzte bedenken sollten. MMW - Fortschritte der Medizin 163, 66–67 (2021). https://doi.org/10.1007/s15006-021-9603-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-021-9603-6

Keywords:

Search

Navigation